Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Judith Wellens, Matthew Edmans, Uri Obolski, Colleen GC McGregor, Peter Simmonds, Marc Turner, Lisa Jarvis, Donal Skelley, Susanna Dunachie, Eleanor Barnes, David W Eyre, Jean-Frederic Colombel, Serre-Yu Wong, Paul Klenerman, James O Lindsey, Jack Satsangi, Craig P Thompson
doi: https://doi.org/10.1101/2021.10.13.21264916

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Back to top
Posted October 18, 2021.
Download PDF
Data/Code
Email
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Judith Wellens, Matthew Edmans, Uri Obolski, Colleen GC McGregor, Peter Simmonds, Marc Turner, Lisa Jarvis, Donal Skelley, Susanna Dunachie, Eleanor Barnes, David W Eyre, Jean-Frederic Colombel, Serre-Yu Wong, Paul Klenerman, James O Lindsey, Jack Satsangi, Craig P Thompson
medRxiv 2021.10.13.21264916; doi: https://doi.org/10.1101/2021.10.13.21264916
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area